Purpura adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 8,698 adverse event reports that record the MedDRA preferred term Purpura. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 397 reports in the 12 months to June 2026 and 417 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 1,107 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 397 (under 0.1%) record this term. Reports for patients 75 and over were 20.1% of the reports that record this term and 9.5% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 143 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Purpura name as a suspect product, in order of name
Drug	Class	Reports with this term
Acetaminophen		82
Acetylcysteine		41
Adalimumab	Tumor necrosis factor blocker	26
Alimta	Folate analog metabolic inhibitor	61
Allopurinol	Xanthine oxidase inhibitor	179
Amitriptyline hydrochloride	Tricyclic antidepressant	44
Amlodipine	Calcium channel blocker	52
Amlodipine besylate	Dihydropyridine calcium channel blocker	51
Amoxicillin	Penicillin-class antibacterial	112
Anakinra	Interleukin-1 receptor antagonist	53
Apremilast	Phosphodiesterase 4 inhibitor	49
Arixtra	Factor Xa inhibitor	35
Aspirin	Nonsteroidal anti-inflammatory drug	80
Atarax		30
Atenolol	beta-Adrenergic blocker	69
Atorvastatin		66
Atorvastatin calcium	HMG-CoA reductase inhibitor	39
Augmentin	Penicillin-class antibacterial	74
Augmentin '125		77
Azathioprine	Purine antimetabolite	39
Azithromycin Anhydrous		36
Bactrim	Dihydrofolate reductase inhibitor antibacterial	89
Bevacizumab	Vascular endothelial growth factor inhibitor	27
Bumetanide	Loop diuretic	51
Capsaicin	Non-Standardized food allergenic extract	53
Carbamazepine	Mood stabilizer	48
Carboplatin	Platinum-based drug	130
Ceftriaxone	Cephalosporin antibacterial	63
Cimetidine	Histamine-2 receptor antagonist	52
Ciprofloxacin	Fluoroquinolone antibacterial	91
Citalopram	Serotonin reuptake inhibitor	45
Clamoxyl		26
Clarithromycin	Macrolide antimicrobial	82
Clindamycin	Lincosamide antibacterial	44
Clonidine	Central alpha-2 adrenergic agonist	50
Clopidogrel	P2Y12 platelet inhibitor	81
Clopidogrel bisulfate	P2Y12 platelet inhibitor	27
Colchicine	Alkaloid	26
Cordarone		28
Cyclophosphamide	Alkylating drug	89
Cytarabine	Nucleoside metabolic inhibitor	50
Dexamethasone	Corticosteroid	123
Diclofenac	Nonsteroidal anti-inflammatory drug	67
Diclofenac sodium	Nonsteroidal anti-inflammatory drug	67
Diltiazem hydrochloride	Calcium channel blocker	44
Dupixent	Interleukin-4 receptor alpha antagonist	100
Eliquis	Factor Xa inhibitor	134
Eltrombopag olamine	Thrombopoietin receptor agonist	41
Enbrel	Tumor necrosis factor blocker	68
Enoxaparin sodium	Low molecular weight heparin	36
Erelzi		40
Erlotinib	Kinase inhibitor	25
Esomeprazole	Proton pump inhibitor	25
Etoposide	Topoisomerase inhibitor	40
Fluorouracil	Nucleoside metabolic inhibitor	53
Fluoxetine	Serotonin reuptake inhibitor	26
Furosemide	Loop diuretic	78
Gabapentin	Anti-epileptic agent	50
Gemcitabine	Nucleoside metabolic inhibitor	26
Heparin		25
Humira		196
Hydroxychloroquine sulfate	Antimalarial	50
Ibuprofen	Nonsteroidal anti-inflammatory drug	91
Imbruvica	Kinase inhibitor	111
Infliximab	Tumor necrosis factor blocker	30
Kardegic		48
Ketamine		54
Keytruda	Programmed death Receptor-1 blocking antibody	64
Lamictal	Anti-epileptic agent	90
Lamisil		27
Lamotrigine	Anti-epileptic agent	66
Lansoprazole	Proton pump inhibitor	119
Lasix	Loop diuretic	26
Lenalidomide	Thalidomide analog	33
Levetiracetam		29
Levofloxacin	Fluoroquinolone antibacterial	100
Lidocaine hydrochloride	Amide local anesthetic	32
Linezolid	Oxazolidinone antibacterial	37
Lithium carbonate	Mood stabilizer	51
Lovenox	Low molecular weight heparin	64
Lyrica		45
Mabthera		46
Magnesium		34
Memantine	N-methyl-D-aspartate receptor antagonist	27
Memantine hydrochloride	N-methyl-D-aspartate receptor antagonist	33
Meropenem	Penem antibacterial	25
Metformin	Biguanide	55
Methotrexate	Folate analog metabolic inhibitor	127
Methylprednisolone	Corticosteroid	45
Metoprolol	beta-Adrenergic blocker	32
Metoprolol tartrate	beta-Adrenergic blocker	40
Mexiletine		43
Mirtazapine		25
Montelukast	Leukotriene receptor antagonist	50
Mycophenolate mofetil	Antimetabolite immunosuppressant	90
Naltrexone hydrochloride	Opioid antagonist	47
Naproxen	Nonsteroidal anti-inflammatory drug	27
Nexium	Proton pump inhibitor	26
Norethindrone	Progestin	25
Nplate	Thrombopoietin receptor agonist	63
Omeprazole	Proton pump inhibitor	36
Ondansetron	Serotonin-3 receptor antagonist	42
Oxaliplatin	Platinum-based drug	54
Paclitaxel	Microtubule inhibitor	31
Pantoprazole	Proton pump inhibitor	58
Pegasys	Interferon alpha	25
Pembrolizumab	Programmed death Receptor-1 blocking antibody	31
Pentoxifylline		55
Piperacillin and tazobactam	Penicillin-class antibacterial	25
Plaquenil	Antimalarial	34
Plavix	P2Y12 platelet inhibitor	70
Potassium chloride	Osmotic laxative	29
Pradaxa	Direct thrombin inhibitor	35
Prednisolone	Corticosteroid	98
Prednisone	Corticosteroid	206
Pregabalin		68
Previscan		33
Ramipril	Angiotensin converting enzyme inhibitor	54
Ranitidine	Histamine-2 receptor antagonist	32
Ranitidine hydrochloride	Histamine-2 receptor antagonist	26
Remicade	Tumor necrosis factor blocker	71
Revlimid	Thalidomide analog	94
Ribavirin	Nucleoside analog antiviral	31
Riboflavin		42
Rifampicin		51
Rifampin	Rifamycin antibacterial	26
Rituximab	CD20-directed cytolytic antibody	156
Rocephin		29
Solu-medrol	Corticosteroid	26
Spironolactone	Aldosterone antagonist	73
Sutent	Kinase inhibitor	42
Tacrolimus	Calcineurin inhibitor immunosuppressant	26
Tazocilline		43
Tegretol	Mood stabilizer	43
Tranexamic acid		30
Vancomycin	Glycopeptide antibacterial	106
Velcade	Proteasome inhibitor	30
Vincristine		26
Vitamin c	Vitamin C	38
Warfarin	Vitamin K antagonist	66
Warfarin sodium	Vitamin K antagonist	44
Xarelto	Factor Xa inhibitor	157
Zelitrex		27

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 56 pharmacologic classes with 50 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Purpura name, in order of name
Class	Reports with this term
Aldosterone antagonist	100
Alkylating drug	121
Amide local anesthetic	55
Angiotensin 2 receptor blocker	72
Angiotensin converting enzyme inhibitor	61
Anti-epileptic agent	257
Antimalarial	109
Antimetabolite immunosuppressant	103
Atypical antipsychotic	57
Benzodiazepine	68
beta-Adrenergic blocker	176
Biguanide	86
Calcineurin inhibitor immunosuppressant	77
Calcium channel blocker	112
CD20-directed cytolytic antibody	182
Central alpha-2 adrenergic agonist	52
Cephalosporin antibacterial	157
Corticosteroid	578
Dihydrofolate reductase inhibitor antibacterial	111
Dihydropyridine calcium channel blocker	60
Factor Xa inhibitor	372
Fluoroquinolone antibacterial	206
Folate analog metabolic inhibitor	234
Glycopeptide antibacterial	110
Histamine-2 receptor antagonist	117
HMG-CoA reductase inhibitor	130
Interleukin-1 receptor antagonist	58
Interleukin-4 receptor alpha antagonist	102
Kinase inhibitor	390
Leukotriene receptor antagonist	68
Lincosamide antibacterial	62
Loop diuretic	155
Low molecular weight heparin	100
Macrolide antimicrobial	98
Mood stabilizer	142
N-methyl-D-aspartate receptor antagonist	60
Nonsteroidal anti-inflammatory drug	393
Nucleoside metabolic inhibitor	186
Opioid agonist	65
P2Y12 platelet inhibitor	185
Penicillin-class antibacterial	227
Phosphodiesterase 4 inhibitor	60
Platinum-based drug	204
Programmed death Receptor-1 blocking antibody	165
Proteasome inhibitor	55
Proton pump inhibitor	290
Purine antimetabolite	56
Serotonin reuptake inhibitor	166
Thalidomide analog	133
Thrombopoietin receptor agonist	134
Topoisomerase inhibitor	58
Tumor necrosis factor blocker	224
Vascular endothelial growth factor inhibitor	50
Vitamin C	50
Vitamin K antagonist	110
Xanthine oxidase inhibitor	179

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Purpura, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Purpura
Age	Reports	Share
Under 2	57	0.7%
2 to 11	146	1.7%
12 to 17	159	1.8%
18 to 44	999	11.5%
45 to 64	2,142	24.6%
65 to 74	1,613	18.5%
75 and over	1,752	20.1%
Age not given	1,830	21%

Sex of the patient in the reports that record Purpura
Sex	Reports	Share
Female	4,155	47.8%
Male	3,917	45%
Unknown or not given	626	7.2%

Age and sex are as the report gives them. 22.3% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Purpura: adverse event reports that record this term. https://reportedreactions.com/reaction/purpura/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Purpura mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page